- in European Union
The opening quarter of 2026 brought a noticeable cooling in mid-market life sciences venture activity. PitchBook data tracking U.S. life sciences venture rounds in the $5–20 million range shows just 65 deals representing $608.6 million of capital invested in Q1 2026. That marks a meaningful pullback from Q1 2025, which saw 87 deals and $868.5 million, and from Q1 2024, which produced 76 deals and $733.1 million in aggregate investment. Average capital per deal has held relatively steady, with roughly $9.4 million in Q1 2026 against $10.0 million in Q1 2025 and $9.6 million in Q1 2024, suggesting the slowdown is being driven by deal volume rather than check size. The context matters: the market recorded 359 deals and $3.75 billion of capital invested in 2025, modestly ahead of 339 deals and $3.48 billion in 2024. Because 2025 was a year of measured growth rather than decline, the Q1 2026 pullback does not simply extend an existing downturn. It instead suggests a potential inflection point that merits close attention in the quarters ahead.
Alongside these shifts in volume, three deal-term trends are reshaping how life sciences rounds at the $5-20 million size are negotiated and completed. Pay-to-play provisions are resurfacing, with lead investors pressing existing holders to fund their pro rata portion or face punitive recapitalizations that cut back existing preferential rights, a clear signal that leverage has shifted back to capital providers. Inside rounds and heavy insider participation have become increasingly common, keeping companies funded but removing arm's-length price discovery and raising conflict-of-interest issues that boards must address through appropriate procedural protections. Fundraising cycles are also stretching, with bridge rounds sized for longer runway and formal extension rounds a more common feature of the landscape. Founders and investors should be prepared for longer cycles, tougher terms, and more deliberate capital decisions.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
[View Source]
